Generic Name and Formulations:
Carisoprodol 200mg, aspirin 325mg, codeine phosphate 16mg; tabs; contains sulfites.
Various generic manufacturers
- Long-term Aspirin-use Associated With Reduced Risk of Gastrointestinal Cancer
- Long-term Aspirin Use Reduces Risk of Major Cancers
- Myeloma Patients Not Receiving Guideline-recommended Thromboprophylaxis
Indications for Carisoprodol/Aspirin/Codeine:
Relief of painful musculoskeletal conditions.
1–2 tabs 4 times daily. May treat up to 2–3 weeks.
<16yrs: not established.
GI complication (eg, bleeding, perforation, obstruction) due to aspirin use. Aspirin-induced asthma. Carbamate sensitivity. NSAID allergy. Porphyria. Post-op pain management in children who have undergone tonsillectomy and/or adenoidectomy.
Risk of respiratory depression and death related to ultra-rapid metabolizers of codeine (esp. children in post-op tonsillectomy and/or adenoidectomy). Peptic ulcer. Gastritis. Acute abdominal conditions. Pancreatic or biliary duct disease. Renal or hepatic dysfunction. History of drug abuse. Asthma. COPD. Lung disease. Increased intracranial pressure. Dehydration. Use lowest effective dose for shortest duration. Elderly. Debilitated. Pregnancy (Cat.D). Nursing mothers: not recommended.
Additive effects with alcohol, CNS depressants, oral anticoagulants, hypoglycemics and plasma bound drugs (eg, methotrexate); use caution. Alcohol, NSAIDs, and oral anticoagulants increase risk of GI bleeding. May reduce antihypertensive effects with concomitant ACEIs, ARBs, beta-blockers, diuretics. Uricosurics antagonized. Urine alkalinizers or acidifiers decrease or increase, respectively, aspirin levels.
Muscle relaxant (central) + salicylate + opioid.
Dizziness, drowsiness, vertigo, ataxia, GI upset or bleeding, epigastric discomfort, tachycardia, orthostatic hypotension, facial flushing, rash, tinnitus; respiratory depression, hypotension.
Formerly known under the brand name Soma Compound w. Codeine.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma